Figure legends
Figure 1. Percentage of individuals with the 34 most common
alterations. The bar graph represents the percentage of individuals with
the most common molecular alterations. Frequently altered genes wereCDKN2A (30.8%, 4/13), TP53 (23.1%, 3/13), and MYC(15.4%, 2/13). Only genes with pathogenicity
by FoundationOne® report is described. VUS is not
involved.
Figure 2. Pie chart displaying the different types of
alterations. Most of the alterations were single nucleotide variants
(37.5%), followed by amplifications (27.0%).
Figure 3. Schematic showing pharmacological intervention
according to actionable genomic alterations. At least one genetic
aberration was detected in 11 patients (84.6%). Actionable mutations
were discovered in 10 patients (76.9%), and seven patients (53.8%) had
clinical trial candidates. No patients were able to receive
biomarker-matched therapy. VUS, variant of uncertain significance.